- Home
- BMA vs BLCO Comparison
BMA vs BLCO Comparison
Compare BMA & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMA
- BLCO
- Stock Information
- Founded
- BMA 1966
- BLCO 1853
- Country
- BMA Argentina
- BLCO Canada
- Employees
- BMA N/A
- BLCO N/A
- Industry
- BMA Commercial Banks
- BLCO Ophthalmic Goods
- Sector
- BMA Finance
- BLCO Health Care
- Exchange
- BMA Nasdaq
- BLCO Nasdaq
- Market Cap
- BMA 5.5B
- BLCO 5.2B
- IPO Year
- BMA 2006
- BLCO 2022
- Fundamental
- Price
- BMA $79.60
- BLCO $15.05
- Analyst Decision
- BMA Strong Buy
- BLCO Hold
- Analyst Count
- BMA 6
- BLCO 14
- Target Price
- BMA $81.70
- BLCO $16.69
- AVG Volume (30 Days)
- BMA 829.4K
- BLCO 535.3K
- Earning Date
- BMA 11-26-2025
- BLCO 10-29-2025
- Dividend Yield
- BMA 2.20%
- BLCO N/A
- EPS Growth
- BMA N/A
- BLCO N/A
- EPS
- BMA 0.50
- BLCO N/A
- Revenue
- BMA $2,573,406,817.00
- BLCO $4,976,000,000.00
- Revenue This Year
- BMA N/A
- BLCO $8.12
- Revenue Next Year
- BMA $3.01
- BLCO $5.81
- P/E Ratio
- BMA $16.95
- BLCO N/A
- Revenue Growth
- BMA N/A
- BLCO 6.23
- 52 Week Low
- BMA $38.30
- BLCO $10.45
- 52 Week High
- BMA $118.42
- BLCO $20.71
- Technical
- Relative Strength Index (RSI)
- BMA 58.45
- BLCO 45.58
- Support Level
- BMA $79.18
- BLCO $14.89
- Resistance Level
- BMA $89.29
- BLCO $16.81
- Average True Range (ATR)
- BMA 5.21
- BLCO 0.69
- MACD
- BMA -1.37
- BLCO -0.04
- Stochastic Oscillator
- BMA 4.20
- BLCO 21.51
About BMA Banco Macro S.A. ADR (representing Ten Class B)
Banco Macro SA is a financial institution and it provides standard banking products and services designed to suit individual needs. It has two categories of customers, retail customers, which include individuals and entrepreneurs, and corporate customers, which include small, medium, and large companies and corporations. In addition, it provides services to four provincial governments. It generates the majority of its revenue from Argentina.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.